Elmiron Pigmentary Maculopathy lawsuit settlement criteria
For years, Elmiron (pentosan polysulfate sodium) was the only FDA-approved oral medication for interstitial cystitis—a chronic bladder condition that affects millions. But by 2026, the medical and legal landscape has shifted dramatically. We now know that long-term Elmiron use can cause a distinctive retinal toxicity known as pigmentary maculopathy, leading to permanent vision loss. At London Pain Relief, we’ve tracked the evolving litigation closely, and the settlement criteria have become more defined as multidistrict litigation (MDL) cases resolve. If you or a loved one took Elmiron and now face vision problems, understanding these criteria is the first step toward accountability.
Key Settlement Criteria Established in the Elmiron MDL 3075 (New Jersey)
The bulk of Elmiron lawsuits were consolidated under MDL 3075 in the District of New Jersey, presided over by Judge Brian R. Martinotti. By early 2026, several bellwether trials and mass settlement frameworks have clarified who qualifies. The core criteria generally include:
- Duration of Use: Most settlement frameworks require cumulative Elmiron use of at least 2 years. Some cases with shorter durations but severe toxicity have been accepted if objective retinal damage is documented.
- Documented Retinal Findings: You must have a definitive diagnosis of pigmentary maculopathy confirmed by a retinal specialist. Key diagnostic evidence includes fundus autofluorescence (FAF) imaging showing hyperautofluorescent spots, optical coherence tomography (OCT) demonstrating outer retinal atrophy, and visual field testing showing paracentral scotomas.
- Exclusion of Alternative Causes: The settlement requires that other causes of maculopathy—such as age-related macular degeneration (AMD), hydroxychloroquine toxicity, or pattern dystrophy—be ruled out by an expert ophthalmologist.
- Timely Filing: All claims must be filed within the applicable statute of limitations, which varies by state. In most cases, this is 2–3 years from the date of diagnosis or discovery of the link to Elmiron.
| Settlement Factor | Typical Threshold | Notes for 2026 Claimants |
|---|---|---|
| Minimum cumulative dose | ≥1,500 grams (approx. 2 years of 300 mg/day) | Lower doses considered with severe retinal findings |
| Retinal imaging proof | FAF + OCT + visual field deficits | Must be performed by a board-certified retinal specialist |
| Exclusion of AMD or other dystrophies | Genetic testing or multimodal imaging | AMD in patients over 60 can complicate claims |
| Statute of limitations | 2–3 years from diagnosis | Varies by state; check with your attorney |
Why the Janssen (Johnson & Johnson) Settlement Framework Matters for London Patients
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, manufactured Elmiron. After years of denying causation, the company began engaging in global settlement discussions in late 2024. By 2026, a structured settlement program is in place for claimants who meet the criteria above. For patients in London, Kentucky—and across the broader Appalachian region—this is critical. Rural patients often face delays in diagnosis because many general ophthalmologists are unfamiliar with Elmiron toxicity. We strongly recommend that any patient with a history of Elmiron use and visual symptoms seek a retinal specialist at the University of Kentucky or Vanderbilt for definitive testing.
“The settlement criteria are not just legal hurdles—they are clinical safeguards. If you have taken Elmiron for more than two years and notice difficulty reading, adjusting to dim light, or seeing straight lines as wavy, you need a retinal exam immediately. Don’t wait for vision to worsen.” — London Pain Relief Editorial Team, referencing the archived case details at londonpainrelief.com and the MDL docket at archive reference.
Practical Steps for Filing an Elmiron Maculopathy Claim in 2026
If you believe you meet the settlement criteria, here is the process we recommend to our readers:
- Obtain your pharmacy records showing the dates and dosages of all Elmiron prescriptions. This is the single most important piece of evidence.
- Schedule a comprehensive retinal evaluation with a specialist who has experience diagnosing drug-induced maculopathy. Bring your pharmacy records and a list of symptoms.
- Consult with an attorney who has experience in the Elmiron MDL. Many firms offer free case reviews and can determine if your statute of limitations has expired.
- Document all vision-related impacts on your daily life—difficulty driving at night, inability to read small print, or trouble recognizing faces. This helps quantify damages.
The landscape for Elmiron litigation continues to evolve, but the path to compensation is clearer now than ever. We remain committed to keeping London Pain Relief readers informed as new developments emerge in this ongoing public health and legal matter.